Filing Flows › Cardiff Oncology (CRDF) › Q2 2025
Cardiff Oncology (CRDF) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 29, 2025
Cardiff Oncology (CRDF) reported revenue of $121K for the second quarter 2025 (Q2 2025), -26% from a year earlier and +11% from the quarter before.
Cardiff Oncology, Q2 2025: revenue $121K (-26% year over year), net loss $13.9M, operating cash flow −$8.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $121K | +11% | -26% |
| Operating profit | −$14.8M | — | — |
| Net earnings | −$13.9M | — | — |
| Operating cash flow | −$8.3M | — | — |
What changed
Revenue was $121K in Q2 2025, down 26% year over year and up 11% from the previous quarter.
Operating costs exceeded revenue by $14.8M, an operating margin of -12212.4%. Total costs grew 17% against a revenue fall of 26%. The fastest-growing cost line was Research & development (+22%). The quarter ended with a net loss of $13.9M, wider than the previous quarter's $13.4M loss.
Operating cash flow was −$8.3M. Non-cash charges added back $94K of depreciation and $1.7M of share-based compensation. Working capital and other items added $3.8M.
Questions
What was Cardiff Oncology's revenue in the second quarter 2025?
Cardiff Oncology (CRDF) reported revenue of $121K for the second quarter 2025 (Q2 2025), -26% from a year earlier and +11% from the quarter before.
Source: Cardiff Oncology 10-Q on SEC EDGAR.